Abstract
The amelioration of glucose tolerance by liraglutide was associated with a significant improvement of early insulin-response during OGTT. The serum C-peptide response to glucagon challenge strongly correlated with the improvement of the early insulin-response. The C-peptide response to glucagon challenge would be useful to predict therapeutic response to liraglutide.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
C-Peptide / blood*
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / physiopathology
-
Dose-Response Relationship, Drug
-
Drug Monitoring
-
Drug Resistance
-
Female
-
Glucagon*
-
Glucagon-Like Peptide 1 / administration & dosage
-
Glucagon-Like Peptide 1 / analogs & derivatives*
-
Glucagon-Like Peptide 1 / therapeutic use
-
Glucagon-Like Peptide-1 Receptor
-
Glucose Tolerance Test
-
Humans
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / therapeutic use*
-
Insulin / blood
-
Insulin / metabolism*
-
Insulin Secretion
-
Insulin-Secreting Cells / drug effects*
-
Insulin-Secreting Cells / metabolism
-
Kinetics
-
Liraglutide
-
Male
-
Middle Aged
-
Receptors, Glucagon / agonists
Substances
-
C-Peptide
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Insulin
-
Receptors, Glucagon
-
Liraglutide
-
Glucagon-Like Peptide 1
-
Glucagon